Pexidartinib, a CSF1 receptor inhibitor, is approved by the FDA for the treatment of adult patients with tenosynovial giant cell tumor, which is a rare and locally aggressive nonmalignant tumor that overexpresses CSF-1 [218,219,220,221]. Here, CSF1 is linked to neoplasm.